Innovative Biomarkers in Alzheimer's Disease and Frontotemporal Dementia (FTD): Preventative and Personalized
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01403519|
Recruitment Status : Unknown
Verified July 2011 by Rambam Health Care Campus.
Recruitment status was: Not yet recruiting
First Posted : July 27, 2011
Last Update Posted : July 27, 2011
Tau pathology and tangles have been associated with cognitive dysfunction causing neurodegeneration. AD, the most abundant tauopathy is characterized by amyloid plaques and tau tangles. An abundance of tau inclusions, in the absence of amyloid deposits, defines Pick's disease (frontotemporal lobar degeneration), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and other diseases including frontal atrophy associated with cognitive clinical dysfunction of frontal dysexecutive syndrome, progressive nonfluent aphasia and semantic dementia as recently reviewed (Gozes 2010). It is the investigators aim to follow other protein expression [as per recent publications (Marksteiner et al., 2011)] in blood and CSF samples from those tauopathies.
Significance: Results should establish the possibility of using tau and other proteins as markers for early detection and disease progression in FTD, also in comparison to Alzheimer's disease (AD).
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||70 participants|
|Official Title:||Innovative Biomarkers in Alzheimer's Disease and Frontotemporal Dementia (FTD): Preventative and Personalized|
|Study Start Date :||July 2011|
|Estimated Primary Completion Date :||January 2014|
|Estimated Study Completion Date :||January 2014|
Alzheimer's disease patients
Patients blood and CSF samples
Blood and CSF samples
Blood ad CSF samples
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01403519
|Haifa, Israel, 31096|
|Contact: Judith Aharon-Peretz, M.D. 972-4-8542637 email@example.com|
|Principal Investigator:||Judith Aharon-Peretz, M.D.||Rambam Hospital, Haifa, Israel|
|Principal Investigator:||Illana Gozes, Ph.D.||Tel Aviv University, Sackler School of Medicine, Israel|